Low-dose heparin as treatment for early disseminated intravascular coagulation during sepsis: A prospective clinical study

Xiao-Li Liu, Xiao-Zhi Wang, Xiu-Xiang Liu, Dong Hao, Yasaman Jaladat, Feng Lu, Ting Sun, Chang-Jun Lv, Xiao-Li Liu, Xiao-Zhi Wang, Xiu-Xiang Liu, Dong Hao, Yasaman Jaladat, Feng Lu, Ting Sun, Chang-Jun Lv

Abstract

The present study aimed to investigate whether low-dose heparin improves the condition of patients suffering from early disseminated intravascular coagulation (pre-DIC) during sepsis. In total, 37 patients were randomly divided into low-dose heparin intervention and control groups. The heparin group received a low-dose of heparin for 5-7 days, while the other group received only saline. The two groups were treated for sepsis. Blood samples were collected at various times and acute physiology and chronic health evaluation (APACHE)-II scores were recorded at day 1 and 7. In addition, the number of days applying mechanical ventilation and in the intensive care unit (ICU) were recorded, as well as the 28-day mortality rate. APACHE-II scores in the two groups decreased following treatment, however, scores in the heparin group decreased more significantly. Prothrombin fragment and thrombin-antithrombin complex levels in the heparin group were significantly decreased. In addition, the number of days applying a ventilator was fewer and the total stay in ICU was significantly shorter compared with the control group. Significantly fewer complications were observed in the heparin group, however, there was no significant difference in the 28-day mortality rate. In conclusion, low-dose heparin improves the hypercoagulable state of sepsis, which subsequently reduces the incidence of DIC or multiple organ dysfunction syndrome, decreasing the number of days of mechanical ventilation and hospitalization.

Keywords: clinical trial; coagulation; disseminated intravascular coagulation; low-dose heparin; sepsis; treatment.

Figures

Figure 1
Figure 1
Hospitalization causes of the patients included in the study.
Figure 2
Figure 2
Various pathogens identified in the sputum or body fluids of the patients.

References

    1. Cornet AD, Smit EG, Beishuizen A, Groeneveld AB. The role of heparin and allied compounds in the treatment of sepsis. Thromb Haemost. 2007;98:579–586.
    1. Bernard GR, Vincent JL, Laterre PF, et al. Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344:699–709.
    1. Barie PS, Hydo LJ, Shou J, Eachempati SR. Efficacy of therapy with recombinant human activated protein C of critically ill surgical patients with infection complicated by septic shock and multiple organ dysfunction syndrome. Surg Infect (Larchmt) 2011;12:443–449.
    1. Dellinger RP, Carlet JM, Masur H, et al. Surviving Sepsis Campaign Management Guidelines Committee. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med. 2004;32:858–873.
    1. Shen JI, Winkelmayer WC. Use and safety of unfractionated heparin for anticoagulation during maintenance hemodialysis. Am J Kidney Dis. 2012;60:473–486.
    1. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20:864–874. No authors listed.
    1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29:1303–1310.
    1. Gerlach H, Keh D. Sepsis in 2003: are we still in the middle of nowhere? Curr Opin Anaesthesiol. 2004;17:97–106.
    1. Feistritzer C, Wiedermann CJ. Effects of anticoagulant strategies on activation of inflammation and coagulation. Expert Opin Biol Ther. 2007;7:855–870.
    1. Hook KM, Abrams CS. The loss of homeostasis in hemostasis: new approaches in treating and understanding acute disseminated intravascular coagulation in critically ill patients. Clin Transl Sci. 2012;5:85–92.
    1. Dempfle CE. Coagulopathy of sepsis. Thromb Haemost. 2004;91:213–224.
    1. Thamas L, Yuan L, Zhu HM, Xia S, editors. Clinical Laboratory Diagnosis: Application and evaluation of results. Shanghai Science and Technology Press; Shanghai: 2004.
    1. Robertson MS. Heparin: the cheap alternative for immunomodulation in sepsis? Crit Care Resusc. 2006;8:235–238.
    1. Wiedermann CJ. Clinical review: molecular mechanisms underlying the role of antithrombin in sepsis. Crit Care. 2006;10:209.
    1. Michaeli B, Martinez A, Revelly JP, et al. Effects of endotoxin on lactate metabolism in humans. Crit Care. 2012;16:R139.
    1. Madoiwa S, Nunomiya S, Ono T, et al. Plasminogen activator inhibitor 1 promotes a poor prognosis in sepsis-induced disseminated intravascular coagulation. Int J Hematol. 2006;84:398–405.
    1. Jaimes F, De la Rosa G, Arango C, et al. A randomized clinical trial of unfractioned heparin for treatment of sepsis (the HETRASE study): design and rationale [NCT00100308] Trials. 2006;7:19.
    1. Jaimes F, De La Rosa G, Morales C, et al. Unfractioned heparin for treatment of sepsis: A randomized clinical trial (The HETRASE Study) Crit Care Med. 2009;37:1185–1196.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel